Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series

Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series

Abstract Background Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has proven to be effective and safe as maintenance therapy and multiline therapy in ovarian cancer, especially in patients with BRCA mutations. This study intended to observe the influence of tumor load on the efficacy and...

Full description

Bibliographic Details
Main Authors: Jing Ni, Rui Zhou, Xianzhong Cheng, Xia Xu, Wenwen Guo, Xiaoxiang Chen
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Journal of Ovarian Research
Subjects:
Recurrent ovarian cancer
Olaparib
Tumor burden
Potential marker
Online Access:http://link.springer.com/article/10.1186/s13048-020-00629-4

Internet

http://link.springer.com/article/10.1186/s13048-020-00629-4

Similar Items